IRWD · Ironwood Pharmaceuticals Inc

Track IRWD — free

$4.41 +0.14 (+3.16%)

Russell 2000 member Rebalance outlook locked

Market Cap

$705.57M

165.24M

Up next

Next earnings call

Nov 16, 2026 Est · unconfirmed · in 11 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 114 metrics

Revenue (TTM)

$389.32M

Trailing 12 months

Net income (TTM)

$129.87M

Trailing 12 months

Revenue growth YoY

+32.6%

Year over year

Operating margin

60.1%

Trailing 12 months

P / E (TTM)

5.5

Trailing earnings · reciprocal yield 18.0%

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

-5.5%

Year over year · fewer shares

Price change (1Y)

+223.5%

Trailing year

Short interest

10.9%

Latest settlement · 6.4 days to cover

View all 114 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Bearish Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.67

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +9%

above

Price vs 50-day avg +3%

above

RSI (14) 52

neutral

MACD trend Negative

52-week position 74%

mid-range

Momentum

relative strength

Very Strong

1-month return −1%

trailing

6-month return +16%

trailing

YTD return +27%

this year

Relative strength +3%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $4 › 200d $4 — 50d above 200d

Institutional flow Distributing

-7% holders QoQ · +24 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

10.93% of float · ▲ +9.2% MoM · 6.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

212 holders — mid 3-yr range

Squeeze score 72

high risk · 0–100

Fundamentals

Excellent

Revenue growth +9%

Y/Y

EPS growth +1400%

Y/Y

Free cash flow $127.0M

Valuation P/E 5.6

below peers

Buyback $32.4M

remaining

Balance sheet $110.4M

net debt

Quant / Vol

risk profile

Very High

Volatility 97%

annualized · 1-yr

Max drawdown −44%

past year

ATR 5.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+9% Bullish

Price vs 50-day avg

+3% Bullish

RSI (14)

52 Neutral

MACD trend

Negative Bearish

52-week position

74% Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $4 › 200d $4 — 50d above 200d

Institutional flow Distributing

-7% holders QoQ · +24 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

10.93% of float · ▲ +9.2% MoM · 6.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

212 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $4 · 74% Range high $5

vs 200-day avg +9% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
IRWD Ironwood Pharmaceuticals Inc this stock	$705.57M	+26.7%	+8.9%	5.6	10.9%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR	$66.37B	—	—	—	0.0%
TAK Takeda Pharmaceutical Co Ltd	$58.66B	+16.9%	—	—	0.1%
GALDY Galderma Group AG/ADR	$47.69B	-1.4%	—	—	0.0%
HLN Haleon plc	$44.35B	-0.4%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

212

% held: 97.6%
Net QoQ: -12.0M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

220

View

Short & Settlement

Short Interest Rising

Shares short

18.1M

Days to cover: 6.4d
Change: +1.5M sh

View

Short Volume

Short vol %

39%

As of: Sep 1, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $4
As of: Aug 13, 2026

View

Off-Exchange

Off-exchange %

40.1%

Week of: Jul 27, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$296.2M

Net income (FY): $24.0M
EPS diluted: $0.15

View

Buybacks

Authorized

$150.0M

Remaining: $32.4M

Spent Remaining

View

Filings

SEC Filings

Latest

10-Q

Filed: Aug 6, 2026
This year: 15

View

Proposed Sales

Value

$560.2K

Shares: 127.9K
Filed: Jul 7, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
IRWD	-2.7%	-0.9%	+16.0%	+0.5%	+26.7%
SPY	-0.5%	-1.2%	+12.6%	-0.7%	+11.7%
vs SPY	-2.2%	+0.3%	+3.4%	+1.2%	+15.0%

Capital returns

Buyback program · as of Mar 31, 2022

Authorized

$150.00M

Spent (derived)

$117.60M

Remaining

$32.40M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1446847 CUSIP 46333X108 13F (30d) 177 filings 174 filers Visit website Investor relations

IRWD · Ironwood Pharmaceuticals Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Versus peers

At a glance

Performance

Capital returns